争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 1 条
2021
英国竞争与市场管理局因甲状腺药片定价对 Advanz 处以罚款
罚款或处罚
英国竞争与市场管理局认定 Advanz 对碘塞罗宁片收取过高且不公平的价格，并对 Advanz 及其前私募股权所有者处以总额超过 1 亿英镑的罚款。
来源摘录
The UK’s competition watchdog has imposed fines of more than £100m on the pharmaceutical company Advanz and its former private equity owners after it was found to have inflated the price of its thyroid tablets by up to 6,000%.
An investigation by the Competition and Markets Authority (CMA) found that the private-equity backed pharmaceutical company charged “excessive and unfair prices” for liothyronine tablets, which are used to treat thyroid hormone deficiency.